Shatavarin IV, a Bioactive Constituent of
📄 Abstract
Shatavarin IV, a steroidal saponin in Cells were treated with shatavarin IV (10 ng/ml) or proprietary ethanolic extract of shatavari root extract (SheVari4 In LPS-induced cells treated with shatavarin IV, IL6 and TNFα levels were reduced by 46% and 50%, respectively, and those of IL-10 and TGF-β were upregulated by 2.74 and 4.4 times with significant reductions in ROS and NO levels. Similar results were observed in presence of SheVari4 The results suggested that the primary bioactive component of
Confidence:
0.2
· 9 полей извлечено
Идентификация (6 полей)
Механизм действия (21 полей)
Mechanism
—
0.00
Mutations (obesity/lean)
Melanocortin 4 receptor (MC4R) mutations
0.90
Activity (obesity)
—
0.00
Activity temporal
—
0.00
Energy balance
MC4R plays a critical role in regulating energy homeostasis
0.90
Appetite
MC4R is part of the hypothalamic leptin-melanocortin pathway central to appetite regulation
0.90
Fat metabolism
Apolipoprotein A-IV restrains fat accumulation in skeletal and myocardial muscles by inhibiting lipogenesis
0.90
Lipolysis
—
0.00
Thermogenesis
Central Apolipoprotein A-IV stimulates thermogenesis in brown adipose tissue
0.90
Muscle metabolism
—
0.00
Inflammation
Shatavarin IV reduces IL6 and TNFα levels, upregulates IL-10 and TGF-β, reduces ROS and NO
0.90
Glucose metabolism
—
0.00
AA metabolism
—
0.00
Hormonal pathways
MC4R is part of the leptin-melanocortin pathway
0.90
Cell death
—
0.00
Adipocyte fibrosis
—
0.00
Upstream (biochem)
—
0.00
Upstream (physiol)
—
0.00
Downstream (biochem)
PI3K-AKT signalling (activated by Apolipoprotein A-IV)
0.90
Downstream (physiol)
—
0.00
PTMs
—
0.00
Экспрессия (8 полей)
Tissue expression
—
0.00
In vitro
Cells treated with shatavarin IV (10 ng/ml) or proprietary ethanolic extract of shatavari root extract (SheVari4) in LPS-induced cells
0.90
In vivo
—
0.00
In silico
—
0.00
Genetic association
—
0.00
Ex vivo
—
0.00
Animal model
—
0.00
Diet/model
—
0.00
Клиника (11 полей)
Drug
—
0.00
Indication
—
0.00
Patient subgroups
—
0.00
Safety concerns
—
0.00
Off-target
—
0.00
Trial stage
—
0.00
Pharma competitors
—
0.00
AE severity
—
0.00
MOA weight loss
—
0.00
Endpoints
—
0.00
Approved
—
0.00